Navigation Links
CROSSEAL*

ProductsCROSSEAL*
Company Ethicon, Inc.
Item CROSSEAL*
Features 
  • Single tip for drip and spray application
  • No needles
  • Clippable tip with innovative clog-reducing design
  • Preps in less than one minute after thawing
  • Thaws within 10 minutes at 37°C
  • Stable at room temperature for 24 hours
  • Unopened vials can be stored at 2° - 8°C for up to 30 days
  • No mixing required Just follow set-up instructions, then draw the BAC and thrombin into the sterile spray application device, and release the vial connectors
  • Forms an elastic clot that anchors firmly to the bleeding site(s)
  • Transparency allows clear wound examination and tissue visibility
Description CROSSEAL* Fibrin Sealant (Human) achieves a secure clot, targeted to the area of the liver where support for hemostasis is needed, when control of bleeding by conventional surgical techniques, including suture, ligature, and cautery, is ineffective or impractical.

CROSSEAL* Fibrin Sealant (Human) delivers a unique formulation of human Biologically Active Component (BAC) and human thrombin with a high-precision, needle-free application device. It may be sprayed to cover the wound with a transparent layer providing good visualization, and forming an elastic clot.

Info Ethicon, Inc.
Customer Service: (800) 4-ETHICON
Web site: http://www.ethicon.com/

Related medicine products :

1. BUN Liquidplus Reagent
2. Urea Nitrogen (BUN) Liquid Reagent
3. ALT (GPT) Liquidplus Reagent
4. ALT (SGPT) Liquid Reagent (Kinetic Method)
5. g-GT Liquid Reagent
6. Gama-GT Liquid Reagent
7. Inorganic Phosphorus (Liquid)
8. Glucose Color Liquidplus Reagent
9. Glucose UV Liquidplus
10. Glucose Hexokinase Liquid
11. Glucose (Liquid) Reagent
TAG: CROSSEAL
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
Medicine Products:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...in production in mice with type 2 diabetes, demons...ss diabetes, say Tulane University gene// therapy ...week in the Early Edition of the Proceedings of th...lt stem cells are grown from donated human bone ma...
...chnology, Jadavpur University, Kolkata and Departm...ege, Andhra Pradesh done a// study on Plumeria Acu...was to evaluate the anti-inflammatory activity of ...on carrageenan, dextran, histamine and serotonin-i...
...d earlier proved that Policosanols present in Cuba...cts. A new study done by// Canadian researchers co... Peter J. H. Jones and Dr. Amira N. Kassis studyi... the University of Manitoba, Winnipeg, conducted t...
...upport the Public Health Foundation of India (PHFI...c Health in India. PHFI is an autonomous// body. T...ne-time grant upto Rs. 65 crore only to the initia...tially proposes to set up two schools. The locatio...
Other Medicine News:Health News:Anti Inflammatory Evaluation Of Plumeria Acuminata Leaves 2
(Date:9/4/2008)...trates potent antiviral activity and favorable saf...RIDGE, Mass., Sept. 4 /- Id...pharmaceutical company engaged,in the discovery an...viral,and other infectious diseases, today announc...y evaluating IDX899, a non-nucleoside reverse,tran...
(Date:9/3/2008)...stion Asked. Wrong Children Studied. Wrong,Conclus...ewswire/ -- A Centers for Disease,Control and Prev...no link,between the MMR vaccine and autism. The Na...es nothing to dispel the growing public concern ov...questions concerning design,and methodology., For...
(Date:9/3/2008)...s National Vascular Disease Awareness Month, CHAR...n Pharmaceuticals,LLC, a clinical-stage drug-devel...reatment of unmet medical needs, announced today t...I clinical trial of its lead drug,candidate trans ...T00725881,on the clinicaltrials.gov Website, is in...
(Date:9/3/2008)...ny to Discuss Phase 3 Plans with FDA, PRINCETON, ...Inc.,announced today that it successfully complet...he company,s new, innovative low-dose, once-weekly... by its internal product,code AG-200-15. The Phase...,primary endpoint of ovulation suppression, cycle ...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Patients over age 60 do well after liver transplantation 2645 1Patients over age 60 do well after liver transplantation 2645 2Toy Blocks Might Boost Toddlers Language Skills 2644 1Toy Blocks Might Boost Toddlers Language Skills 2644 2HSN Is Seeing Pink with Susan G Komen for the Cure During National Breast Cancer Awareness Month 2642 1HSN Is Seeing Pink with Susan G Komen for the Cure During National Breast Cancer Awareness Month 2642 2HSN Is Seeing Pink with Susan G Komen for the Cure During National Breast Cancer Awareness Month 2642 3Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer 2640 1Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer 2640 2
...4, 2007 /PRNewswire-FirstCall/ Haemacure,Corporati...mpany,today announced the preliminary findings of...s. , Preliminary findings confirm the presence of ... in significant worldwide,markets, including album...findings take on a strategic significance for Haem...
... 2007 /PRNewswire-FirstCall/ --,Bristol-Myers Squi...fficacy and safety of ORENCIA(R) (abatacept) from ... study in children with juvenile,idiopathic arthri...ne or more disease-modifying anti- rheumatic drugs...rosis factor (TNF) antagonists.,The results demons...
Other Medicine Technology:Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 2Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 3Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 4Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 2Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 3Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 4Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 5Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 6